Estetrol and the possibilities of its clinical use

Czech version

Authors: Křepelka Petr
Authors‘ workplace: Ústav pro péči o matku a dítě, Praha Katedra gynekologie a porodnictví IPVZ, Praha 3. LF UK, katedra gynekologie a porodnictví, Praha
Published in: Ceska Gynekol 2021; 86(3): 217-221
Category:
doi: https://doi.org/10.48095/cccg2021217

Overview

Combined hormonal contraceptive methods are one of the most commonly used methods of planned parenthood. They show high contraceptive effectiveness, reasonable cycle control and bring several non-contraceptive benefits. A limitation of the widespread use of combined hormonal contraception is the risk of cardiovascular complications in individuals with specific risk factors. The risk of cardiovascular complications is related to the used estrogen component. Currently, the most common use of estrogen in combined hormonal contraception is ethinyl estradiol and estradiol valerate. The good estrogenic part of combined oral contraceptives is estetrol, a hormone produced exclusively by the fetal liver. Estetrol exhibits a tissue-selective receptor activity. Unlike previously used estrogens, it does not negatively affect the production of liver proteins and blood clotting parameters. Estetrol is not a perspective for combined hormonal contraception only. It is also promising for treating and preventing osteoporosis, hormonal therapy of menopausal syndrome, and vulvovaginal atrophy syndrome.

Keywords:

estetrol – hormonal contraception – Estrogens – drospirenone – complications of hormonal contraception

Sources

1. Hagen AA, Barr M, Diczfalusy E. Metabolism of 17b-oestradiol-4-14C in early infancy. Acta Endocrinol 1965; 49: 207–220.

2. Fishman J, Solomon S. Metabolism, production and excretion rates of 15alpha-hydroxyestriol in late pregnancy. J Clin Endocrinol Metab 1972; 35 (3): 339–344. doi: 10.1210/jcem-35- 3-339.

3. Schut HA, Bowman JM, Solomon S. Precursor role of 15alpha-hydroxyestradiol and 15alpha-hydroxyandrostenedione in formation of estetrol. Can J Biochem 1978; 56 (2): 101–106. doi: 10.1139/o78-016.

4. Holinka CF, Diczfalusy E, Coelingh Bennink HJ. Estetrol: a unique steroid in human pregnancy. J Steroid Biochem Mol Biol 2008; 110 (1–2): 138–143. doi: 10.1016/j.jsbmb.2008.03.027.

5. Coelingh Bennink F, Holinka CF, Visser M et al. Maternal and fetal estetrol levels during pregnancy. Climacteric 2008; 11 (Suppl 1): 69–72. doi: 10.1080/13697130802056321.

6. Kundu N, Wachs M, Iverson GB et al. Comparison of serum unconjugated estriol and estetrol in normal and complicated pregnancies. Obstet Gynecol 1981; 58 (3): 276–281.

7. Sciarra JJ, Tagatz GE, Notation AD et al. Estriol and estetrol in amniotic fluid. Am J Obstet Gynecol 1974; 118 (5): 626–642. doi: 10.1016/ s0002-9378 (16) 33738-3.

8. Heikkilä J, Luukkainen T. Urinary excretion of estriol and 15alpha-hydroxyestriol in complicated pregnancies. Am J Obstet Gynecol 1971; 110 (4): 509–521. doi: 10.1016/0002-9378 (71) 90692-2.

9. Visser M, Holinka CF, Coelingh Bennink HJ. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric 2008; 11 (Suppl 1): 31–40. doi: 10.1080/13697130802056511.

10. Coelingh Bennink HJ, Verhoeven C, Zimmerman Y et al. Pharmacokinetics of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Climacteric 2017; 20 (3): 285–289. doi: 10.1080/13697137. 2017.1291608.

11. Visser M, Foidart JM, Coelingh Bennink HJ. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism. Climacteric 2008; 11 (Suppl 1): 64–68. doi: 10.1080/13697130802050340.

12. Abot A, Fontaine C, Buscato M et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor a modulation, uncoupling nuclear and membrane activation. EMBO Mol Med 2014; 6 (10): 1328–1346. doi: 10.15252/emmm.201404112.

13. Hammond GL, Hogeveen KN, Visser M et al. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric 2008; 11 (Suppl 1): 41–46. doi: 10.1080/13697130701851814.

14. Coelingh Bennink HJ, Heegaard AM, Visser M et al. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric 2008; 11 (Suppl 1): 2–14. doi: 10.1080/ 13697130701798692.

15. Heegaard AM, Holinka CF, Kenemans P et al. Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test. Climacteric 2008; 11 (Suppl 1): 22–28. doi: 10.1080/ 13697130701842490.

16. Coelingh Bennink HJ, Singer C, Simoncini T et al. Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model. Climacteric 2008; 11 (Suppl 1): 29. doi: 10.1080/13697130802040 325.

17. Guivarc‘h E, Buscato M, Guihot AL et al. Predominant role of nuclear versus membrane estrogen receptor a in arterial protection: implications for estrogen receptor a modulation in cardiovascular prevention/safety. J Am Heart Assoc 2018; 7 (13): e008950. doi: 10.1161/JAHA. 118.008950.

18. Valéra MC, Noirrit-Esclassan E, Dupuis M et al. Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis. Mol Cell Endocrinol 2018; 477: 132–139. doi: 10.1016/j.mce.2018.06.010.

19. Mawet M, Maillard C, Klipping C et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Health Care 2015; 20 (6): 463–475. doi: 10.3109/13625187.2015.1068934.

20. Holinka CF, Brincat M, Coelingh Bennink HJ. Preventive effect of oral estetrol in a menopausal hot flush model. Climacteric 2008; 11 (Suppl 1): 15–21. doi: 10.1080/13697130701822807.

21. Coelingh Bennink HJ, Verhoeven C, Zimmerman Y et al. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas 2016; 91: 93–100. doi: 10.1016/j.maturitas.2016.06.017.

22. Coelingh Bennink HJ, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric 2008; 11 (Suppl 1): 47–58. doi: 10.1080/13697130802073425.

23. Klipping C, Duijkers I, Mawet M et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception 2021; 103 (4): 213–221. doi: 10.1016/j.contraception.2021.01.001.

24. Duijkers I, Klipping C, Kinet V et al. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. Contraception 2021; 103 (6): 386–393. doi: 10.1016/j.contraception.2021.03.003.

25. Douxfils J, Klipping C, Duijkers I et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception 2020; 102 (6): 396– –402. doi: 10.1016/j.contraception.2020.08.015.

26. Kluft C, Zimmerman Y, Mawet M et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception 2017; 95 (2): 140– –147. doi: 10.1016/j.contraception.2016.08.018.

27. Apter D, Zimmerman Y, Beekman L et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care 2017; 22 (4) : 260–267. doi: 10.1080/ 13625187.2017.1336532.